基于AGREEⅡ的急性冠脉综合征患者抗血小板药物治疗的指南评价  

Evaluation of Guidelines for Antiplatelet Therapy in Patients with Acute Coronary Syndrome Based on AGREEⅡ

作　　者：宋鹏飞 王婷[2] 董亚琳[1] 张璐[1] SONG Pengfei;WANG Ting;DONG Yalin;ZHANG Lu(Dept.of Pharmacy,the First Affiliated Hospital of Xi’an Jiaotong University Health Science Center,Xi’an 710061,China;Dept.of Rheumatology and Immunology,the First affiliated Hospital of Xi’an Jiaotong University Health Science Center,Xi’an 710061,China)

机构地区：[1]西安交通大学医学院第一附属医院药学部,西安710061 [2]西安交通大学医学院第一附属医院风湿免疫科,西安710061

出　　处：《中国医院用药评价与分析》2024年第1期5-8,12,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：陕西省科学技术厅重点研发计划项目(No.2021SF-328)。

摘　　要：目的:采用临床指南研究与评估系统Ⅱ(AGREEⅡ)工具,对2010—2019年国内外公开发表的急性冠脉综合征(ACS)患者抗血小板药物治疗相关临床实践指南进行方法学评价。方法:选取2010—2019年国内外公开发表的ACS患者抗血小板药物治疗指南及相关文献为研究对象,使用AGREEⅡ对其进行系统评价,并分析各指南推荐内容的差异。结果:共纳入相关文献10篇,其中7篇治疗指南,3篇专家建议与共识。AGREEⅡ各领域的平均得分,范围和目的为(82.5±8.7)%,参与人员为(67.5±15.3)%,制定的严谨性为(68.7±18.2)%,表达的清晰性为(89.3±4.0)%,应用性为(68.1±13.8)%,编辑的独立性为(54.8±12.3)%,总体评价为(65.7±12.3)%。组内相关系数及95%CI为0.89(0.72~0.92),说明研究员评分一致性较高。指南均推荐术后使用阿司匹林+P2Y12受体拮抗剂双联抗血小板治疗。结论:临床实践指南用药推荐术后使用阿司匹林+P2Y12受体拮抗剂双联抗血小板治疗,用药疗程为12个月。ACS患者非必要无需进行基因检测。OBJECTIVE:To evaluate the clinical practice guidelines for antiplatelet therapy in patients with acute coronary syndrome(ACS)published domestically and internationally from 2010 to 2019 according to appraisal of guidelines for research and evaluationⅡ(AGREEⅡ)tool.METHODS:Guidelines and related literature for the treatment of antiplatelet drugs in patients with ACS published domestically and internationally from 2010 to 2019 were selected as the research object,and AGREEⅡwas used to perform systematic review,and the differences between recommended contents of the guidelines were analyzed.RESULTS:A total of 10 relevant guidelines were included,including 7 treatment guidelines and 3 expert recommendations and consensus.Mean scores for each domain of AGREEⅡwere(82.5±8.7)%for scope and purpose,(67.5±15.3)%for participants,(68.7±18.2)%for rigor of formulation,(89.3±4.0)%for clarity of presentation,(68.1±13.8)%for applicability,(54.8±12.3)%for editorial independence,and(65.7±12.3)%for overall evaluation.The intra-group correlation coefficient and 95%CI was 0.89(0.72-0.92),indicating a high degree of consistency in researcher scores.All guidelines recommend aspirin+P2Y12 receptor antagonist combined with antiplatelet therapy after surgery.CONCLUSIONS:Clinical guidelines recommend aspirin+P2Y12 receptor antagonist combined with antiplatelet therapy for 12 months.Genetic testing is not necessary in patients with ACS.

关 键 词：急性冠脉综合征 抗血小板药物治疗 指南评价 

分 类 号：R973[医药卫生—药品]